Literature DB >> 33362203

Therapeutic response monitoring after targeted therapy in an orthotopic rat model of hepatocellular carcinoma using contrast-enhanced ultrasound: Focusing on inter-scanner, and inter-operator reproducibility.

Hwaseong Ryu1, Jung Hoon Kim2,3,4, Seunghyun Lee2,3, Joon Koo Han2,3,4.   

Abstract

PURPOSE: To assess therapeutic response monitoring after targeted therapy in an orthotopic rat model of hepatocellular carcinoma (HCC) using CEUS with focusing on inter-scanner and inter-operator reproducibility.
MATERIALS AND METHODS: For reproducibility, CEUS was performed using two different US scanners by two operators in sixteen rat models of HCC. Using perfusion analysis software (VueBox ®), eleven parameters were collected, and intra-class correlation coefficient (ICC) was used to analyze reproducibility. Then seventeen rat models of HCC were divided into treatment group (n = 8, 30 mg/kg/day sorafenib for five days) and control group (n = 9). CEUS was performed at baseline and 14 days after first treatment, and changes of perfusion parameters were analyzed.
RESULTS: In treatment group, CEUS perfusion parameters showed a significant change. The peak enhancement (PE, 2.50 x103±1.68 x103 vs 5.55x102±4.65x102, p = 0.010) and wash-in and wash out AUC (WiWoAUC, 1.07x105±6.48 x104 vs 2.65x104±2.25x104, p = 0.009) had significantly decreased two weeks after treatment. On the contrary, control group did not show a significant change, including PE (1.15 x103±7.53x102 vs 9.43x102± 7.81 x102, p = 0.632) and WiWoAUC (5.09 x104±3.25x104 vs 5.92 x104±3.20x104, p = 0.646). For reproducibility, the various degrees of inter-scanner reproducibility were from poor to good (ICC: <0.01-0.63). However, inter-operator reproducibility of important perfusion parameters, including WiAUC, WoAUC, and WiWoAUC, ranged from fair to excellent (ICC: 0.59-0.93) in a different scanner.
CONCLUSION: Our results suggest that CEUS is useful for assessment of the treatment response after targeted therapy and with fair to excellent inter-operator reproducibility.

Entities:  

Year:  2020        PMID: 33362203      PMCID: PMC7757904          DOI: 10.1371/journal.pone.0244304

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  32 in total

1.  [Functional and early evaluation of treatments in oncology: interest of ultrasonographic contrast agents].

Authors:  N Lassau; M Lamuraglia; J Leclère; V Rouffiac
Journal:  J Radiol       Date:  2004-05

2.  A new formalism for the quantification of tissue perfusion by the destruction-replenishment method in contrast ultrasound imaging.

Authors:  Marcel Arditi; Peter J A Frinking; Xiang Zhou; Nicolas G Rognin
Journal:  IEEE Trans Ultrason Ferroelectr Freq Control       Date:  2006-06       Impact factor: 2.725

3.  Post-operative monitoring of tissue transfers: advantages using contrast enhanced ultrasound (CEUS) and contrast enhanced MRI (ceMRI) with dynamic perfusion analysis?

Authors:  P Lamby; L Prantl; C Fellner; S Geis; E M Jung
Journal:  Clin Hemorheol Microcirc       Date:  2011       Impact factor: 2.375

4.  Non-invasive monitoring of the therapeutic response in sorafenib-treated hepatocellular carcinoma based on photoacoustic imaging.

Authors:  Seunghyun Lee; Jung Hoon Kim; Jae Hwan Lee; Jeong Hwa Lee; Joon Koo Han
Journal:  Eur Radiol       Date:  2017-07-27       Impact factor: 5.315

5.  Antiangiogenic tumor treatment: noninvasive monitoring with contrast pulse sequence imaging for contrast-enhanced grayscale ultrasound.

Authors:  Jianhua Zhou; Wei Zheng; Longhui Cao; Min Liu; Feng Han; Anhua Li
Journal:  Acad Radiol       Date:  2010-03-11       Impact factor: 3.173

6.  Time-Intensity Curves Obtained after Microbubble Injection Can Be Used to Differentiate Responders from Nonresponders among Patients with Clinically Active Crohn Disease after 6 Weeks of Pharmacologic Treatment.

Authors:  Emilio Quaia; Michele Sozzi; Roberta Angileri; Antonio Giulio Gennari; Maria Assunta Cova
Journal:  Radiology       Date:  2016-05-18       Impact factor: 11.105

7.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

Review 8.  Clinical relevance of contrast-enhanced ultrasound in monitoring anti-angiogenic therapy of cancer: current status and perspectives.

Authors:  Michele Lamuraglia; S Lori Bridal; Mathieu Santin; Gianni Izzi; Olivier Rixe; Angelo Paradiso; Olivier Lucidarme
Journal:  Crit Rev Oncol Hematol       Date:  2009-07-09       Impact factor: 6.312

9.  Evaluation of the Reproducibility of Bolus Transit Quantification With Contrast-Enhanced Ultrasound Across Multiple Scanners and Analysis Software Packages-A Quantitative Imaging Biomarker Alliance Study.

Authors:  Michalakis A Averkiou; Eric K Juang; Madison K Gallagher; Maria Alejandra Cuevas; Stephanie R Wilson; Richard G Barr; Paul L Carson
Journal:  Invest Radiol       Date:  2020-10       Impact factor: 6.016

10.  Simultaneous Assessment of Myocardial Perfusion, Wall Motion, and Deformation during Myocardial Contrast Echocardiography: A Feasibility Study.

Authors:  Giacomo Zoppellaro; Lucia Venneri; Rajdeep S Khattar; Wei Li; Roxy Senior
Journal:  Echocardiography       Date:  2016-02-01       Impact factor: 1.724

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.